545 related articles for article (PubMed ID: 30894208)
1. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H
Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208
[TBL] [Abstract][Full Text] [Related]
2. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D
Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246
[TBL] [Abstract][Full Text] [Related]
3. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
[TBL] [Abstract][Full Text] [Related]
4. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
[TBL] [Abstract][Full Text] [Related]
5. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
Kameda H; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham N; Tanaka Y
Mod Rheumatol; 2020 Mar; 30(2):239-248. PubMed ID: 31268376
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
Genovese MC; Fleischmann R; Kivitz A; Lee EB; van Hoogstraten H; Kimura T; St John G; Mangan EK; Burmester GR
Arthritis Res Ther; 2020 Jun; 22(1):139. PubMed ID: 32522251
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
Burmester GR; Lin Y; Patel R; van Adelsberg J; Mangan EK; Graham NM; van Hoogstraten H; Bauer D; Ignacio Vargas J; Lee EB
Ann Rheum Dis; 2017 May; 76(5):840-847. PubMed ID: 27856432
[TBL] [Abstract][Full Text] [Related]
10. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
[TBL] [Abstract][Full Text] [Related]
13. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
Genovese MC; van Adelsberg J; Fan C; Graham NMH; van Hoogstraten H; Parrino J; Mangan EK; Spindler A; Huizinga TWJ; van der Heijde D;
Rheumatology (Oxford); 2018 Aug; 57(8):1423-1431. PubMed ID: 29746672
[TBL] [Abstract][Full Text] [Related]
14. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
15. CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study.
Mease PJ; Jeka S; Jaller JJ; Kitumnuaypong T; Louthrenoo W; Mann H; Matsievskaia G; Soriano ER; Jia B; Wang C; Nie J; Hsia E
J Rheumatol; 2018 Jan; 45(1):22-31. PubMed ID: 29093159
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P
Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
[TBL] [Abstract][Full Text] [Related]
17. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR
Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
[TBL] [Abstract][Full Text] [Related]
19. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
Emery P; Fleischmann RM; Moreland LW; Hsia EC; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel BA; Doyle MK; Visvanathan S; Xu W; Rahman MU
Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
[TBL] [Abstract][Full Text] [Related]
20. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
